Histamine Phosphate

Catalog No.S4117

For research use only.

Histamine acts directly on the blood vessels to dilate arteries and capillaries mediated by both H 1- and H 2-receptors.

Histamine Phosphate Chemical Structure

CAS No. 51-74-1

Purity & Quality Control

Choose Selective Histamine Receptor Inhibitors

Other Histamine Receptor Products

Biological Activity

Description Histamine acts directly on the blood vessels to dilate arteries and capillaries mediated by both H 1- and H 2-receptors.
Features Histamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function.
Histamine H1 receptor [1] Histamine H2 receptor [1]
In vitro

Histamine (10 μM) gives a larger inositol monophosphate accumulation in bovine adrenal chromaffin cells. Histamine (10 μM) stimulates the level of radioactivity into the InsP3-containing fraction in bovine adrenal chromaffin cells. Histamine (100 μM) stimulates incorporation into the InsP3-containing eluate in a less extent than for angiotensin I1 and bradykinin. [1]

In vivo Histamine phosphate (0.025 mg/kg) produces a mean increase in basilar blood flow of 145% of control in dogs. Histamine phosphate produces considerable increases in basilar blood flow as well as a decrease in femoral arterial blood pressure in dogs when injected intravenously and measured with an electromagnetic flow transducer. [2] Histamine phosphate (4 μg/kg) causes lymph flow to increase from 6.0 to 27.0 (SEM) ml/h in unanesthetized sheep. Histamine phosphate (4 μg/kg) also causes increases in lung water, pulmonary vascular resistance, arterial PCO2, pH, and hematocrit, and decreases in cardiac output and arterial PO2 in unanesthetized sheep. [3] Histamine phosphate (8.3 mg/kg/min) causes no significant change in pulmonary lymph flow (QL) or protein concentration (CL) in anesthetized open-chested dogs, however, both are increased after alloxan. Histamine phosphate (8.3 mg/kg/min) also causes no significant change in the pulmonary capillary membrane filtration coefficient (Kf) and the maximum capillary pressure (PCcritical) in anesthetized open-chested dogs. [4] Histamine phosphate (50 mg/kg) produces a pronounced rise in acid secretion but the output of pepsin remained unchanged in the unanaesthetized intact rat. Histamine phosphate (50 mg/kg) produces maximal stimulation of gastric acid secretion and is free from toxic effects in the unanaesthetized intact rat. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 307.14


CAS No. 51-74-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=C(NC=N1)CCN.OP(=O)(O)O.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04828317 Not yet recruiting Other: Pork Challenge Allergy;Food University of Virginia May 1 2021 Not Applicable
NCT04699604 Recruiting Drug: Levocetirizine Dihydrochloride|Drug: Placebo Allergic Asthma Children''s Mercy Hospital Kansas City April 28 2021 Phase 3
NCT04913623 Recruiting Procedure: Hip Replacement Arthroplasty Complications University Clinical Centre of Kosova March 23 2021 --
NCT04534036 Recruiting Dietary Supplement: PDS-08|Other: Placebo Constipation|Signs and Symptoms|Digestive Signs and Symptoms|Infrequent or Difficult Evacuation Seed Health|Curebase Inc. August 13 2020 Not Applicable
NCT05022108 Completed Biological: Alpha bisabolol gel Wounds and Injuries Universidade do Vale do Sapucai April 1 2020 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Histamine Phosphate | Histamine Phosphate ic50 | Histamine Phosphate price | Histamine Phosphate cost | Histamine Phosphate solubility dmso | Histamine Phosphate purchase | Histamine Phosphate manufacturer | Histamine Phosphate research buy | Histamine Phosphate order | Histamine Phosphate mouse | Histamine Phosphate chemical structure | Histamine Phosphate mw | Histamine Phosphate molecular weight | Histamine Phosphate datasheet | Histamine Phosphate supplier | Histamine Phosphate in vitro | Histamine Phosphate cell line | Histamine Phosphate concentration | Histamine Phosphate nmr